Tickeron's Halloween AI Sale 10 Years of AI Innovation. Faster AI. Smarter Trading. Instant Market Intelligence.
tickeron.com/trading-investi…
Why Is Steakholder Foods ( $STKH) Stock Down 24.68% Today?
(Find out why any stock moved today on Tickeron.)
STKH shares fell roughly 24.68% intraday, last trading near $0.58 versus a prior close of $0.77.
The decline extends a severe selloff in which the stock lost more than half its value in the previous session on extraordinary volume.
The primary driver is heavy shareholder dilution tied to a series of recent capital raises, pre-funded warrants, and an equity line of credit.
A shareholder-approved, multi-thousand-fold increase in authorized share capital reinforces the financing overhang.
$CAG $SMPL $USNA $PETZ $BGS
tickeron.com/blogs/why-is-st…
$MRVL is down over 10% after reporting that
it's looking to acquire $LITE
tickeron.com/compare/LITE-vs…
Materialise ($MTLS) Falls -23% in 30 Days After Q3 Earnings Reaction
Materialise (MTLS) shares declined roughly 23% over the trailing 30 days, with the move concentrated after the company's third-quarter 2026 earnings release on October 28.
Third-quarter revenue rose 2.1% year over year to €67.67 million but landed slightly below consensus, while adjusted EBIT and adjusted EBITDA both declined from the prior-year period.
tickeron.com/blogs/materiali…
Why Inovio Pharmaceuticals ( $INO) Stock Is Down -24% in the Last 30 Days
The slide reflects heightened uncertainty ahead of the U.S. FDA's October 30, 2026 target action date for INO-3107, the company's lead candidate for recurrent respiratory papillomatosis (RRP). $JNJ $MRK
tickeron.com/ticker/INO/sign…
LUMENTUM $LITE is UP by more than 10% in after-hours
tickeron.com/ticker/LITE/
F5 ($FFIV) Drops -15% Over 30 Days: Earnings Beat Overshadowed by Guidance
F5 (FFIV) shares declined roughly 15% over the trailing 30 days, with most of the move concentrated in a single session following its fiscal fourth-quarter 2026 earnings report.
The company beat quarterly estimates — revenue of $917 million (up 13% year over year) and adjusted EPS of $4.42 versus the $4.26 consensus — but softer-than-expected fiscal 2027 guidance drove the sell-off.
tickeron.com/blogs/f5-ffiv-d…
Altria ($MO) vs $VOO: High-Yield Dividend Stock or Broad S&P 500 Exposure?
Different asset types: MO is a single high-dividend tobacco company, while VOO is a passively managed exchange-traded fund (ETF) tracking the S&P 500 Index across roughly 500 large-cap U.S. stocks.
Return profile diverges: MO has delivered strong year-to-date gains driven by pricing power and its smoke-free transition, while VOO offers broad, diversified market exposure with roughly 13% year-to-date appreciation.
tickeron.com/blogs/altria-mo…
Michael Burry Warns: The AI Boom Is “Catastrophically Vulnerable”!
The investor famous for predicting the 2008 financial crisis is warning about a potential financial crisis in AI infrastructure.
According to claims attributed to Burry about Anthropic's IPO filing:
🔴 1. Massive Computing Commitments
Anthropic reportedly has $537 BILLION in future computing obligations, potentially reaching $800 BILLION with additional deals.
🔴 2. Revenue vs. Commitments
With approximately $65B in annualized revenue, potential computing commitments could reach 12 times annualized sales.
These are future obligations, not necessarily debt immediately due.
🔴 3. Big Tech Exposure
About half of the reported $537B involves cloud providers:
$AMZN $GOOGL $MSFT
These companies are investing billions in AI infrastructure while supplying computing capacity to AI developers.
🔴 4. Growth Slows, Costs Accelerate
📉 Revenue growth reportedly slowed from 144% to 46%.
📈 Computing costs reportedly increased 78%.
💥 THE DOMINO EFFECT
If AI demand slows, the consequences could spread across:
☁️ Cloud: $AMZN $GOOGL $MSFT
🖥️ Semiconductors: $NVDA $AMD $AVGO
⚡ Data centers: $VRT $ETN
🤖 WHAT SHOULD INVESTORS DO?
AI may transform the economy, but that doesn't guarantee every AI investment will be profitable.
Use Tickeron's AI Screener, AI V3.0, and FLM-powered AI Trading Agents to evaluate valuations, catalysts, and market trends.
$Tickeron #MichaelBurry #AI #NVDA #StockMarket
Educational only. Not investment advice.
$FEPI vs $JEPQ: Weighing Concentrated Tech Income Against a Broader Nasdaq Approach
FEPI is a concentrated, equal-weighted fund of roughly 15 large-cap technology names that sells covered calls on individual stocks, while JEPQ runs a broader, actively managed Nasdaq-100-style portfolio of about 100-plus holdings with an index-level options overlay.
JEPQ is materially cheaper, charging a 0.35% expense ratio versus 0.65% for FEPI.
tickeron.com/blogs/fepi-vs-j…
Earnings Shock: $FTNT −25%, $NOW −16%,
$GOOG Alphabet Shares Fall Nearly -10%!
October 28, 2026 | After-Hours Market
Wall Street is sending a clear message: Good earnings aren't always good enough.
📉 $FTNT −25.41% | Fortinet
Revenue increased 20% YoY to $2.08B, and GAAP EPS reached $0.86.
Despite raising guidance and expanding its share buyback authorization, shares plunged.
Narrative: Strong reported growth doesn't guarantee a positive reaction when expectations are already high.
📉 $NOW −15.77% | ServiceNow
Shares dropped sharply following quarterly results described as mixed.
Narrative: Enterprise software valuations can be particularly sensitive to growth expectations and forward guidance.
📉 $GOOGL −9.87% | $GOOG −9.62% | Alphabet
Alphabet's share classes experienced substantial after-hours selling.
Narrative: Investors are closely watching AI infrastructure spending, cloud growth, and the profitability of major technology platforms. The dashboard does not establish the precise cause of this decline.
📉 $AMRZ −5.85% | Amrize
Revenue of $3.77B missed the $3.85B consensus, despite adjusted EPS of $1.05 beating expectations.
Narrative: Cost inflation and interest-rate pressure remain important considerations.
📉 $TYL −5.80% | Tyler Technologies
EPS beat expectations, but revenue missed estimates. SaaS revenue grew 21.2%.
Narrative: Even healthy recurring-revenue growth may not offset disappointing headline results.
📉 $MRAM −5.66% | Everspin Technologies
Revenue increased to $20.6M, but the company reported a GAAP loss of $0.29 per share, affected by litigation and regulatory expenses.
Narrative: Revenue growth alone cannot eliminate concerns about profitability.
⚠️ $PANW −6.85% | Palo Alto Networks
Shares declined amid cybersecurity vulnerability and patching developments rather than a confirmed earnings catalyst.
🤖 Where Are the Buying Opportunities?
Use Tickeron's AI Screener and FLM-powered AI Trading Agents to identify candidates and assess potential entry timing.
$Tickeron #Earnings #StockMarket #AITrading #BuyTheDip
Educational only. Not investment advice.
Earnings Winners: Why $PRCH and $GKOS Surged After Hours!
October 28, 2026 | Earnings Season
🟢 $PRCH +23.71% | Porch Group
Revenue reached $143.86M, beating Wall Street's $133.44M estimate.
EPS of $0.10 dramatically exceeded expectations of $0.014.
Narrative: Stronger-than-expected profitability can rapidly change investor sentiment. Porch demonstrated how an earnings surprise can trigger a major repricing.
🟢 $GKOS +17.10% | Glaukos
Revenue surged 58% YoY to $211M.
EPS of $0.47 exceeded expectations for a $0.10 loss.
Management projected 2026 revenue of $775M–$785M.
Narrative: Healthcare innovation combined with accelerating revenue growth and improving profitability can attract investors even during broader market weakness.
🤖 What Can Tickeron's AI Tell Us?
A strong earnings report doesn't automatically mean investors should chase a rally.
Tickeron's FLM-powered AI Trading Agents can also help analyze market trends and potential entry and exit signals.
$Tickeron #Earnings #Stocks #AITrading #Investing
Educational only. Not investment advice.
$GDX vs $GDXJ: Large-Cap Gold Miners ETF Compared to Junior Miners
Different market-cap exposure: GDX targets established large- and mid-cap gold miners, while GDXJ focuses on smaller, "junior" miners with higher growth and higher volatility profiles.
Similar costs: Both are passively managed index funds with nearly identical expense ratios—0.51% for GDX and 0.52% for GDXJ.
tickeron.com/blogs/gdx-vs-gd…
Enanta Pharmaceuticals ($ENTA): Watching the -9.6% Pullback and Pipeline Progress
Enanta Pharmaceuticals (ENTA) is a clinical-stage biotechnology company developing small-molecule antivirals for respiratory and liver diseases, backed by a recurring hepatitis C (HCV) royalty stream from AbbVie.
The stock has traded in a narrow band around the low-to-mid teens, declining roughly 9.6% over the trailing 30 days as of late October 2026.
tickeron.com/blogs/enanta-ph…
$GKOS UP +18% AFTER HOURS
tickeron.com/ticker/GKOS/
$FTNT DOWN -25% after hours despite beating Q3 estimates and raising its FY26 revenue & EPS outlook. Q3 revenue grew 20%, billings 29%, and product sales 37%.
tickeron.com/ticker/FTNT/
Microsoft $MSFT surges over +5% after reporting stronger than expected Q3 earnings. $GOOG
tickeron.com/ticker/MSFT/
Greenland Energy ($GLND): -31% Drop Over 30 Days While Holding +65% Gains for the Quarter
Greenland Energy (GLND) has declined roughly 31% over the past 30 days, falling from a closing price of $4.49 on September 28, 2026, to about $3.11, as a late-September speculative surge unwound.
The pullback followed a sharp rally driven by the U.S.–Denmark–Greenland security agreement and Greenland Energy's extension of its Jameson Land farm-out agreement with 80 Mile plc.
tickeron.com/blogs/greenland…
Shenandoah Telecommunications ($SHEN) Slides -16% Over 30 Days as Fiber Buildout Caution Persists
Shenandoah Telecommunications (SHEN) declined roughly 16% over the last 30 days, falling from a closing price of $11.35 to around $9.53.
The pullback extended a longer slide: over the trailing quarter, shares have lost close to 20% from their late-July level near $11.84.
tickeron.com/blogs/shenandoa…
$INKT vs $REVB: Weighing Two Clinical-Stage Biotech Equities
Both INKT and REVB are clinical-stage biotechnology companies with no approved products and limited revenue, making them high-risk, catalyst-driven equities.
INKT has advanced its lead cell therapy into a randomized Phase 2 trial and reported narrower losses, while REVB recently completed a 1-for-7 reverse stock split and is preparing a pivotal Phase 2/3 study.
tickeron.com/blogs/inkt-vs-r…



